It is not credible for institutions to treat company behaviour as external to system performance, particularly in the context of a more assertive US stance on pharmaceutical pricing. Yet what review processes exist are mostly about additional adjustments by stakeholders to the institutional framework. How about changing the framework to recognise realities?
The importance of humility and understanding the other side of the equation
March 22, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 17 April
April 17, 2026 - - Podcast -
Australia, the US, and their different choices about health system trade-offs
April 17, 2026 - - Latest News -
Why hospitals, and not medicines, dominate America’s health spending gap
April 17, 2026 - - Latest News -
New strategic alliance for Biointelect aims to fast track life sciences innovation
April 17, 2026 - - Latest News -
Mark Butler confirms new and expanded cancer medicine listings
April 17, 2026 - - Latest News -
Why US health spending looks much higher than it really is
April 16, 2026 - - Latest News -
Pharmacy prescribing reform signals shift in NSW primary care with Victoria to follow
April 15, 2026 - - Latest News
